Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili.
Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Curr Opin Oncol. 2022 Jan 1;34(1):19-28. doi: 10.1097/CCO.0000000000000799.
comprehensive molecular characterization of adrenocortical carcinoma (ACC) through next-generation sequencing and bioinformatics analyses is expanding the number of targets with potential prognostic and therapeutic value. We performed a critical review of recent published literature on genotyping of ACC.
423 studies were published between 2019 and 2021. After manual curation we summarized selected evidence in two thematic areas: germline deoxyribonucleic acid (DNA) variations, genomic alterations and prognosis.
the evolving genomic landscape of ACC requires target validation in terms of prognostic and predictive value within scientific consortia. Although the existing multiple driver genes are difficult targets in the perspective of precision oncology, alterations in DNA damage repair genes or in promoter hypermethylation could open new venues for repurposing of existing drugs in ACC.
通过下一代测序和生物信息学分析对肾上腺皮质癌（ACC）进行全面的分子特征分析，扩大了具有潜在预后和治疗价值的靶点数量。我们对最近发表的关于 ACC 基因分型的文献进行了批判性回顾。
2019 年至 2021 年期间发表了 423 项研究。经过人工整理，我们总结了两个主题领域的精选证据：种系脱氧核糖核酸（DNA）变异、基因组改变与预后。
ACC 不断变化的基因组景观需要在科学联盟中验证其在预后和预测方面的价值。尽管现有的多个驱动基因在精准肿瘤学的角度来看是难以攻克的靶点，但 DNA 损伤修复基因或启动子超甲基化的改变可能为 ACC 中现有药物的重新利用开辟新途径。
